Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of Bruce L.A. Carter, Ph.D. to its Board of Directors. Dr. Carter will also serve as a member of the Compensation and the Nominating and Corporate Governance Committees. The Board also announced today the resignation of Helmut M. Schuhsler, Ph.D. as a director.
“Dr. Carter’s combination of scientific expertise and operational experience in the healthcare field will be invaluable to Enanta as we continue to research infectious disease areas and advance our lead compounds,” stated Jay R. Luly, Ph.D. President and Chief Executive Officer. “I would also like to thank Helmut for his leadership, guidance and dedication to Enanta, which we have benefited from since he first joined our Board in 1998. I wish him continued success.”
“It is a privilege to join Enanta’s Board at this exciting time in the company’s history,” commented Bruce L.A. Carter, Ph.D. “I look forward to my service on the Board and to contributing to the company’s future success.”
Dr. Carter has extensive experience in the pharmaceutical industry including positions as an executive and director. He currently serves as a director of Dr. Reddy’s Ltd., Immune Design Corp, Xencor Inc. and Regulus Therapeutics and is currently an Affiliate Professor, Department of Biochemistry at the University of Washington, Seattle, Washington.
Dr. Carter served as Executive Chairman of Immune Design Corp. from 2009 to 2011. From 2000 to 2009, he held executive management positions at ZymoGenetics, Inc., where he served as President and Chief Executive Officer until 2009, and continued as Chairman of the Board until 2010, when the company was acquired by Bristol Myers Squibb. He worked at Novo Nordisk from 1994 to 2000 as Corporate Executive Vice President and Chief Scientific Officer. Previously he was at ZymoGenetics, which was acquired by Novo Nordisk, where he served as their President from 1988 to 1994 and as Vice President Research and Development from 1986 to 1988. Dr. Carter began his career at G.D. Searle & Co. Ltd. where from 1982 to 1986 he was Head of Molecular Genetics.